
News and Updates

The Rocky Mountain Life Sciences Investor & Partnering Conference
Grateful to have participated in the Rocky Mountain Life Sciences Investor and Partnering Conference in Breckenridge, Colorado! The Reglagene team had valuable conversations with industry leaders and investors, and CEO Richard Austin shared exciting updates on our lead asset in preclinical development. We're energized by the momentum and eager for what's next!
Presentation at BioCentury, in Nashville
Thank you, BioCentury Inc., Nashville! The Reglagene team had a great three days engaging in insightful discussions with key stakeholders and industry leaders. CEO Richard Austin took the stage to share exciting updates on our lead asset currently in preclinical development.
Welcoming Ben Maurey as a Commercial Advisor
We are excited to welcome Ben Maurey to Reglagene as our commercial-focused advisor on our Advisory Board. Ben comes to Reglagene after 8 years in the oncology space with a wide variety of roles and responsibilities.
Bio San Diego 2024
Thinking Small has lead to the biggest breakthrough. Yesterday, Reglagene's CEO Richard Austin presented at the BIO International Convention in San Diego. Here, he discussed how Reglagene's therapy has the unique ability to cross through the blood-brain barrier and fight brain cancer. Reach out to learn more!
Thinking Small at The Angel Capital Association
Thank you Angel Capital Association for selecting Reglagene as one of your Innovation Funders Showcase companies! CEO Richard Austin captivated the audience in Columbus, Ohio with a presentation on how "Thinking Small" has changed the way we think about treating brain cancer.
Reglagene at Destination Startup
Thrilled to have been part of Destination Startup hosted by Venture Partners at CU Boulder! Reglagene's CEO, Richard Austin, captivated a full room at 1:00 PM MDT with an exciting presentation focused on business and scientific milestones. A big thank you to Tech Launch Arizona for the invitation and to Stephen Miller for coordinating this fantastic event!
Reglagene Expands to Houston and Joins TMC's Accelerator for Cancer Therapeutics
Reglagene's lead product, RGN6024, was accepted into TMC's Accelerator for Cancer Therapeutics. Find the full announcement below or on the EIN Presswire.
BIO CEO & Investor Conference 2024 - NYC
Pitching to a full house during Reglagene's presentation at BIO CEO & Investor Conference, in Times Square, New York City!
Reglagene Attends the Student Industry Networking Event (SINE)
Last week, Teri Suzuki, Lilian Patrón, and Michael Abrahamson participated in the 16th Annual BIO5/BIOSA Student Industry Networking Event.